TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04715269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: Alprazolam 0.5 mg will be given when the patient with acute coronary syndrome would present to the emergency

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Empty capsule
Study: NCT02201888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive training
Description: Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
Study: NCT01400802

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Dosage form- Subcutaneous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Dosage form- Subcutaneous Injection
Study: NCT01890447

Intervention type: OTHER
Intervention: Web-based survey questionnaire
Description: Data collection will be done via web-based questionnaires generated by Sawtooth Software. Subjects will be asked for their ideal alternative (acceptance to immunisation) by selecting the factors that suit them the most. The subjects are then presented several sets of alternatives built around their ideal choice.

Intervention type: OTHER
Intervention: Web-based survey questionnaire
Description: Data collection will be done via web-based questionnaires generated by Sawtooth Software. Subjects will be asked for their ideal alternative (acceptance to immunisation) by selecting the factors that suit them the most. The subjects are then presented several sets of alternatives built around their ideal choice.

Intervention type: OTHER
Intervention: Web-based survey questionnaire
Description: Data collection will be done via web-based questionnaires generated by Sawtooth Software. Subjects will be asked for their ideal alternative (acceptance to immunisation) by selecting the factors that suit them the most. The subjects are then presented several sets of alternatives built around their ideal choice.
Study: NCT02317289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Detection of freezing
Description: single wireless inertial sensor placed on the patients's lower limbs to detect freezing of gaitin Parkinsonian patients
Study: NCT04920500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Cytarabine liposome for injection
Description: Induction 1: \[100 U/m²\] i.v. d1,3,5 Induction 2: \[100 U/m²\] i.v. d1,3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vyxeos、Daunorubicin Cytarabine liposome for injection
Description: Induction 1: \[100 U/m²\] i.v. Vyxeos（d1）,Daunorubicin Cytarabine liposome for injection（d3、d5） Induction 2: \[100 U/m²\] i.v. Daunorubicin Cytarabine liposome for injection（d1、d3 ）
Study: NCT01422187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Description: Taliglucerase infusion every two weeks for 21 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Description: Taliglucerase infusion every two weeks for 21 months
Study: NCT03578549

Intervention type: DEVICE
Intervention: Pulse Oximetry
Description: Pulse Oximeter is being applied with a special holding tool to test the oximeter for its ability to measure pulpal blood flow, but no effect of the oximeter is being measured. Thus, to that degree the use is observational rather than interventional.
Study: NCT01820975

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein intake

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: No protein intake
Study: NCT03585634

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dads in Gear Program
Study: NCT02201888

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computerized active condition
Description: Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU: Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities.
Study: NCT03464955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Based Distractions
Description: Technology based distractions (VR headsets, AR headset, tablets, or BERT projector)
Study: NCT01349322

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated whole breast irradiation
Description: Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 15 fractions of 2.67 Gy for a total dose of 40.0 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent boost
Description: 15 fractions of 3.2 Gy for a total dose of 48 Gy to the lumpectomy cavity. Given concurrently with treatment to the entire breast. May be given by either electron beam or photon beams using either 3D-CRT or IMRT.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Sequential boost
Description: 6 fractions of 2.0 Gy per fraction for a total dose of 12 Gy or 7 fractions of 2.0 Gy for a total dose of 14 Gy to the lumpectomy cavity. May be given by either electron beam or photon beams using either 3D-CRT or IMRT. Begins without a treatment break after completion of the treatment to the entire breast.
Study: NCT03127774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Route of administration: Intraperitoneal for tumor treatment. Dose of 250 mg/m2~Drug 1 of the hyperthermic intraperitoneal chemotherapy (HIPEC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Description: Route of administration: Intravenous Loading dose of 7.5 gm/m2 over 20 minutes followed by 2.13 gm/m2/hr for 12 hours~Drug 2 given intravenously during hyperthermic intraperitoneal chemotherapy (HIPEC)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Standard of care: Surgical procedure used to remove tumors from patients with peritoneal tumors.
Study: NCT04751409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo CXR

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT-chest

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT-chest
Study: NCT01373372

Intervention type: DRUG
Group type: OTHER
Intervention: Acthrel
Description: Powder for reconstitution, 1.0 mcg/kg body weight to a maximum of 100 mcg, delivered one time via IV over one minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthrel
Description: Powder for reconstitution, 1.0 mcg/kg body weight to a maximum of 100 mcg, delivered one time via IV over one minute.
Study: NCT04751409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT-chest

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Follow-Up
Description: Undergo intense follow-up

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Follow-Up
Description: Undergo intense follow-up
Study: NCT00345254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: severing cord
Description: The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
Study: NCT02981498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox Protocol
Description: Oxaliplatin , fluorouracil, and leucovorin
Study: NCT02305511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral venous catheterization
Description: Cannulation using standard method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jamshidi
Description: intraosseous access using the Jamshidi device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIG
Description: intraosseous access using the BIG device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook
Description: intraosseous access using the Cook device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EZIO
Description: intraosseous access using the EZIO device
Study: NCT03284359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Consent Nudge Bundle
Description: The pre-consent nudge bundle survey was developed by the study team and incorporates several behavioral interventions into a bundle of 5 types of nudges: (i) injunctive norms; (ii) descriptive norms; (iii) duty of reciprocity; (iv) self-prophecy; and (v) foot-in-the-door. Injunctive norms involve the perception of what behavior is acceptable, while descriptive norms highlight what behaviors others are engaging in. The duty of reciprocity is the sense that one should repeat pro-social behavior for which they have benefited from. The foot-in-the-door nudge involves asking a participant to perform a small request which has a high consent rate followed by a larger request. The bundle consists of six questions and one statement.
Study: NCT04011930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
Study: NCT03261466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium breve BR03 and Bifidobacterium breve B632

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT01083732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: Experimental dose chosen based on age and weight
Study: NCT02331485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO + Acticoat group
Description: Comparison between Pico and Acticoat dressing change after 3 and 7 days with standard Mepor dressing change on daily basis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO + Acticoat group
Description: Comparison between Pico and Acticoat dressing change after 3 and 7 days with standard Mepor dressing change on daily basis.
Study: NCT01746576

Intervention type: OTHER
Group type: OTHER
Intervention: Use of impedance threshold device during spontaneous ventilation
Study: NCT02593760

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered PO QD for up to 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib will be administered at a dose of 150 mg PO QD for up to 48 weeks.
Study: NCT00564421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine nasal spray, low concentration, low dose volume
Description: 2 sprays in each nostril, dosed twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo nasal spray
Description: 2 sprays in each nostril, dosed twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine nasal spray, low concentration, high dose volume
Description: 2 sprays in each nostril, dosed twice a day
Study: NCT04751409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Follow-Up
Description: Undergo limited follow-up

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Technique
Description: Undergo imaging
Study: NCT00564421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine nasal spray, high concentration, low dose volume
Description: 2 sprays in each nostril, dosed twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine nasal spray, high concentration, high dose volume
Description: 2 sprays in each nostril, dosed twice a day
Study: NCT04751409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Technique
Description: Undergo imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Technique
Description: Undergo imaging
Study: NCT02240472

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission of axillary clearance
Description: The intervention is the omission of completion axillary clearance after the detection of sentinel node macrometastasis
Study: NCT03528213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Lactate light dose
Description: bolus 2.5ml/kg then 0.25ml/kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Lactate high dose
Description: bolus 2.5ml/kg then 0.5ml/kg/h

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: normal saline at physician discretion
Study: NCT02042703

Intervention type: DEVICE
Intervention: anterior segment OCT

Intervention type: DEVICE
Intervention: anterior segment OCT

Intervention type: DEVICE
Intervention: anterior segment OCT
Study: NCT03130894

Intervention type: OTHER
Intervention: Plasma TMAO concentration
Description: Plasma TMAO concentration

Intervention type: OTHER
Intervention: Plasma TMAO concentration
Description: Plasma TMAO concentration
Study: NCT04751409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04613765

Intervention type: BEHAVIORAL
Intervention: Measure adherence behaviors
Description: Conducted in the ambulatory setting of two Brussels hospitals, the MADESIO mixed-method study design combine sequentially a first quantitative explorative questionnaire-based study with a second in depth qualitative approach.~The first 4 visits questionnaire-based survey prospectively measures adherence to OAMs and identify associated risk factors in the two sub-groups of ambulatory patients with various haematological malignancies. A combination of validated self-reported measures able to measure medication taking behaviours, assess both intentional and unintentional adherence, identify associated risk factors was selected.~The second qualitative phase, based on the McGill Illness narrative interview design, deeper address patients' therapeutic adherence and subjective meanings.

Intervention type: BEHAVIORAL
Intervention: Measure adherence behaviors
Description: Conducted in the ambulatory setting of two Brussels hospitals, the MADESIO mixed-method study design combine sequentially a first quantitative explorative questionnaire-based study with a second in depth qualitative approach.~The first 4 visits questionnaire-based survey prospectively measures adherence to OAMs and identify associated risk factors in the two sub-groups of ambulatory patients with various haematological malignancies. A combination of validated self-reported measures able to measure medication taking behaviours, assess both intentional and unintentional adherence, identify associated risk factors was selected.~The second qualitative phase, based on the McGill Illness narrative interview design, deeper address patients' therapeutic adherence and subjective meanings.
Study: NCT03005912

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional acoustic telephony
Description: Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
Study: NCT00099944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride 4 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride 4 mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride 4 mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAF237 placebo
Study: NCT02349607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771 300mg
Description: PF-05089771 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771 300 mg + pregabalin 300 mg
Description: PF-05089771 300 mg + pregabalin 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placeco

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin 300 mg
Description: pregabalin 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen 600 mg
Description: ibuprofen 600 mg
Study: NCT01316757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT04089930

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunogenicity
Description: anti-VZV IgG titer and cell-mediated immunity (VZV-stimulated T cell spots)

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunogenicity
Description: anti-VZV IgG titer and cell-mediated immunity (VZV-stimulated T cell spots)
Study: NCT01316757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00448851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inhaled allergen challenge
Description: Subjects will inhale gradually increasing concentrations of Dermatophagoides farinae until a 15% drop in FEV1 is noted
Study: NCT00874640

Intervention type: BIOLOGICAL
Intervention: Gadobutrol (Gadovist, BAY86-4875)
Description: Patients with indication for a MRT or MR-Angiography and for whom the radiologist has decided to use the contrast medium gadobutrol
Study: NCT02179736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane
Study: NCT01915121

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Intervention
Description: 1-hour educational and training sessions. In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition Intervention
Description: 1-hour educational and training sessions. In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
Study: NCT02111096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfonylurea
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea
Description: Administered orally
Study: NCT00294736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: Dose Escalation: 150-350+ mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: Dose Escalation: 150-350+ mg/day
Study: NCT00804219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBE vaccination and influenza vaccination
Description: FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBE vaccination and influenza vaccination
Description: FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBE vaccination and influenza vaccination
Description: FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x
Study: NCT01419210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-study Questionnaire
Description: Assess the interest level for various CAM topics through feedback received from the study participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Presentations
Description: Attend a two-hour presentation each week for four weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAM Therapies
Description: Integrate the CAM topics of highest interest into participant's regular care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-study Questionnaire
Description: Examine the data to see if it supports recommending a larger, multi-site, integrative CAM program for other women with ovarian cancer